Skip to main content
ISTH 2023 Main banner
Back

    State-of-the-Art Session

    Immunothrombosis

    Therapeutic Approaches to Immunothrombosis

    SOA 06.2 - Inhibition of PAD4 in Immunothrombosis

    Sunday, June 25, 2023
    08:25 – 08:50 ET
    Room: 517
    Session Available As: Live-Stream and On-Demand

      Speaker(s)

    • Lukas Heger, MD (he/him/his)

      Research Fellow
      Program in Cellular and Molecular Medicine, Boston Children's Hospital / Harvard Medical School Department of Cardiology and Angiology University Medical Center, Faculty of Medicine
      Rottenburg am Neckar, Germany

    Please view the 2023 RPTH State-of-the-Art Illustrated Capsules here.

    Learning Objectives:

    • Upon completion, participants will be able to specify the role of Peptidylarginine deiminase 4 (PAD4) in clinical thromboinflammation.
    • Upon completion, participants will be able to identify Peptidylarginine deiminase 4 (PAD4) as an important catalyst of the citrullination of inter- and extra-cellular proteins driving various functional responses that may lead to disease.
    • Upon completion, participants will be able to explain, how inhibition of PAD4 could be a viable therapeutic target to attenuate collateral damage in chronic inflammation.